Quenching-induced deactivation of photosensitizer by nanoencapsulation to improve phototherapy of cancer

Journal of Drug Targeting

Volumn 17, Issue 8, 2009, Pages 619-626

  Zeisser Labouèbe, Magali ^a   Mattiuzzo, Marc ^a   Lange, Norbert ^a   Gurny, Robert ^a   Delie, Florence ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

drug loading; Hypericin; in vitro; nanoparticles; photodynamic therapy; quenching

Indexed keywords

HYPERICIN; NANOPARTICLE; PHOTOSENSITIZING AGENT; DRUG DERIVATIVE; PERYLENE;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SELECTIVITY; ENZYME INACTIVATION; FLUORESCENCE; HUMAN; HUMAN CELL; INTERNALIZATION; NANOENCAPSULATION; NEOPLASM; OVARY CARCINOMA; PHOTOCHEMICAL QUENCHING; PHOTODYNAMIC THERAPY; PHOTODYNAMICS; PHOTOTOXICITY; PRIORITY JOURNAL; FEMALE; METHODOLOGY; OVARY TUMOR; PHOTOTHERAPY; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; FLUORESCENCE; HUMANS; NANOPARTICLES; OVARIAN NEOPLASMS; PERYLENE; PHOTOSENSITIZING AGENTS; PHOTOTHERAPY;

EID: 70350438224     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860903118930     Document Type: Article

References (51)

1. Agostinis P, Vantieghem A, Merlevede W, De Witte PAM. (2002). Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol, 34, 221-241. (Pubitemid 34159138)
2. Allison RR, Mota HC, Bagnato VS, Sibata CH. (2008). Bionanotechnology and photodynamic therapy - State of the art review. Photodiagn Photodyn Ther, 5, 19-28. (Pubitemid 351337662)
3. Aveline BM, Hasan T, Redmond RW. (1995). The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA). J Photochem Photobiol B, 30, 161-169.
4. Campo MA, Gabriel D, Kucera P, Gurny R, Lange N. (2007). Polymeric photosensitizer prodrugs for photodynamic therapy. Photochem Photobiol, 83, 958-965. (Pubitemid 47087386)
5. Chen J, Stefflova K, Niedre MJ, Wilson BC, Chance B, Glickson JD, Zheng G. (2004). Protease-triggered photosensitizing beacon based on singlet oxygen quenching and activation. J Am Chem Soc, 126, 11450-11451. (Pubitemid 39244956)
6. Clo E, Snyder JW, Ogilby PR, Gothelf KV. (2007). Control and selectivity of photosensitized singlet oxygen production: challenges in complex biological systems. Chembiochem, 8, 475-481. (Pubitemid 47183640)
7. Clo E, Snyder JW, Voigt NV, Ogilby PR, Gothelf KV. (2006). DNAprogrammed control of photosensitized singlet oxygen production. J Am Chem Soc, 128, 4200-4201.
8. D'Hallewin MA, Bezdetnaya L, Guillemin F. (2002). Fluorescence detection of bladder cancer: a review. Eur Urol, 42, 417-425. (Pubitemid 35396724)
9. Davda J, Labhasetwar V. (2002). Characterization of nanoparticle uptake by endothelial cells. Int J Pharm, 233, 51-59. (Pubitemid 34230418)
10. Derycke AS, de Witte PA. (2004). Liposomes for photodynamic therapy. Adv Drug Deliv Rev, 56, 17-30. (Pubitemid 38045422)
11. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. (1997). The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res, 14, 1568-1573. (Pubitemid 28009208)
12. Dolmans DEJG, Fukumura D, Jain RK. (2003). Photodynamic therapy for cancer. Nat Rev Cancer, 3, 380-387. (Pubitemid 37328858)
13. Etzlstorfer C, Falk H. (2000). Concerning the association of hypericin tautomers and their hypericinate ions. Monatshefte für Chemie, 131, 333-340.
14. Falk H, Meyer J. (1994). On the homo- and heteroassociation of hypericin. Monatshefte für Chemie, 125, 753-762.
15. Gabriel D, Campo MA, Gurny R, Lange N. (2007). Tailoring proteasesensitive photodynamic agents to specific disease-associated enzymes. Bioconjug Chem, 18, 1070-1077. (Pubitemid 47122626)
16. Gaumet M, Gurny R, Delie F. (2009). Localization and quantification of biodegradable particles in an intestinal cell model: The influence of particle size. Eur J Pharm Sci, 36, 465-473.
17. Hamblin MR, Miller JL, Rizvi I, Loew HG, Hasan T. (2003). Pegylation of charged polymer-photosensitiser conjugates: effects on photodynamic efficacy. Br J Cancer, 89, 937-943. (Pubitemid 37175819)
18. Hamblin MR, Miller JL, Rizvi I, Ortel B, Maytin EV, Hasan T. (2001). Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer. Cancer Res, 61, 7155-7162. (Pubitemid 32946509)
19. Hopper C. (2000). Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol, 1, 212-219.
20. Huygens A, Kamuhabwa AR, de Witte PA. (2005). Stability of different formulations and ion pairs of hypericin. Eur J Pharm Biopharm, 59, 461-468. (Pubitemid 40342520)
21. Iyer AK, Khaled G, Fang J, Maeda H. (2006). Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today, 11, 812-818. (Pubitemid 44280021)
22. Jocham D, Stepp H, Waidelich R. (2007). Photodynamic diagnosis in urology: state-of-the-art. Eur Urol, 53, 1138-1150.
23. Kamuhabwa A, Agostinis P, Ahmed B, Landuyt W, Van Cleynenbreugel B, Van Poppel H, De Witte P. (2004). Hypericin as a potential phototherapeutic agent in superficial transitional cell carcinoma of the bladder. Photochem Photobiol Sci, 3, 772-780. (Pubitemid 39302978)
24. Komagoe K, Tamagake K, Katsu T. (2006). The influence of aggregation of porphyrins on the efficiency of photogeneration of hydrogen peroxide in aqueous solution. Chem Pharm Bull (Tokyo), 54, 1004-1009.
25. Konan YN, Berton M, Gurny R, Allemann E. (2003a). Enhanced photodynamic activity of meso-tetra(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. Eur J Pharm Sci, 18, 241-249. (Pubitemid 36349275)
26. Konan YN, Cerny R, Favet J, Berton M, Gurny R, Allemann E. (2003b). Preparation and characterization of sterile sub- 200 nm meso-tetra(4- hydroxylphenyl)porphyrin-loaded nanoparticles for photodynamic therapy. Eur J Pharm Biopharm, 55, 115-124. (Pubitemid 36120503)
27. Konan YN, Gurny R, Allemann E. (2002). State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B, 66, 89-106. (Pubitemid 34240266)
28. Konan-Kouakou YN, Boch R, Gurny R, Allemann E. (2005). In vitro and in vivo activities of verteporfin-loaded nanoparticles. J Control Release, 103, 83-91. (Pubitemid 40248563)
29. Lavie G, Mazur Y, Lavie D, Meruelo D. (1995). The chemical and biological properties of hypericin - A Compound with a broadspectrum of biological activities. Med Res Rev, 15, 111-119.
30. McCarthy JR, Perez JM, Bruckner C, Weissleder R. (2005). Polymeric nanoparticle preparation that eradicates tumors. Nano Lett, 5, 2552-2556. (Pubitemid 43088911)
31. Mosinger J, Mosinger B. (1995). Photodynamic sensitizers assay: rapid and sensitive iodometric measurement. Experientia, 51, 106-109.
32. Oba T. (2007). Photosensitizer nanoparticles for photodynamic therapy. Curr Bioact Compd, 3, 239-251.
33. Qaddoumi MG, Ueda H, Yang J, Davda J, Labhasetwar V, Lee VH. (2004). The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res, 21, 641-648. (Pubitemid 38457287)
34. Rijcken CJ, Hofman JW, van Zeeland F, Hennink WE, van Nostrum CF. (2007). Photosensitiser-loaded biodegradable polymericmicelles: preparation, characterisation and in vitro PDT efficacy. J Control Release, 124, 144-153. (Pubitemid 350101885)
35. Saw CL, Olivo M, Soo KC, Heng PW. (2005). Delivery of hypericin for photodynamic applications. Cancer Lett, 241, 23-30.
36. Schneider R, Tirand L, Frochot C, Vanderesse R, Thomas N, Gravier J, Guillemin F, Barberi-Heyob M. (2006). Recent improvements in the use of synthetic peptides for a selective photodynamic therapy. Anticancer Agents Med Chem, 6, 469-488. (Pubitemid 44377781)
37. Sharman WM, Allen CM, van Lier JE. (1999). Photodynamic therapeutics: basic principles and clinical applications. Drug Discov Today, 4, 507-517. (Pubitemid 29497854)
38. Sharman WM, van Lier JE, Allen CM. (2004). Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev, 56, 53-76. (Pubitemid 38045424)
39. Smith RP. (2002). Photodynamic therapy. Curr Probl Cancer, 26, 67-108.
40. Solban N, Rizvi I, Hasan T. (2006). Targeted photodynamic therapy. Lasers Surg Med, 38, 522-531.
41. Tanielian C, Schweitzer C, Mechin R, Wolff C. (2001). Quantum yield of singlet oxygen production by monomeric and aggregated forms of hematoporphyrin derivative. Free Radic Biol Med, 30, 208-212. (Pubitemid 32121798)
42. Theodossiou T, Spiro MD, Jacobson J, Hothersall JS, Macrobert AJ. (2004). Evidence for intracellular aggregation of hypericin andthe impact on its photocytotoxicity in PAM 212 murine keratinocytes. Photochem Photobiol, 80, 438-443. (Pubitemid 40174467)
43. Triesscheijn M, Baas P, Schellens JHM, Stewart FA. (2006). Photodynamic therapy in oncology. Oncologist, 11, 1034-1044. (Pubitemid 44564813)
44. Van de Putte M, Roskams T, Bormans G, Verbruggen A, de Witte PA. (2006). The impact of aggregation on the biodistribution of hypericin. Int J Oncol, 28, 655-660.
45. van Dongen GA, Visser GW, Vrouenraets MB. (2004). Photosensitizerantibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev, 56, 31-52. (Pubitemid 38045423)
46. van Nostrum CF. (2004). Polymeric micelles to deliver photosensitizers for photodynamic therapy. Adv Drug Deliv Rev, 56, 9-16. (Pubitemid 38045421)
47. Verma S, Watt GM, Mai Z, Hasan T. (2007). Strategies for enhanced photodynamic therapy effects. Photochem Photobiol, 83, 996-1005. (Pubitemid 47438530)
48. Wynn JL, Cotton TM. (1995). Spectroscopic properties of hypericin in solution and at surfaces. J Phys Chem, 99, 4317-4323.
49. Zeisser-Labouèbe M, Lange N, Gurny R, Delie F. (2006a). Hypericinloaded nanoparticles for the photodynamic treatment of ovarian cancer. Int J Pharm, 326, 174-181. (Pubitemid 44647750)
50. Zeisser-Labouèbe M, Vargas A, Delie F. (2006b). Nanoparticles for photodynamic therapy of cancer. In: Kumar CS (ed.), Nanomaterials for Cancer Therapy (Vol. 6, pp. 40-86). Weinheim: Wiley-VCH.
51. Zheng G, Chen J, Stefflova K, Jarvi M, Li H, Wilson BC. (2007). Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation. Proc Natl Acad Sci USA, 104, 8989-8994. (Pubitemid 47175424)